Bioresponsive dextrin-rhEGF conjugates: In vitro evaluation in models relevant to its proposed use as a treatment for chronic wounds

Molecular Pharmaceutics

Volumn 7, Issue 3, 2010, Pages 699-707

  Hardwicke, Joseph ^a,b   Moseley, Ryan ^a   Stephens, Phil ^a   Harding, Keith ^a   Duncan, Ruth ^a,b   Thomas, David W ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Chronic wounds; Dextrin epidermal growth factor conjugate; Fibroblasts; Keratinocytes; Polymer therapeutics

Indexed keywords

AMYLASE; DEXTRIN; ELASTASE; GAMMA UROGASTRONE; RECOMBINANT PLATELET DERIVED GROWTH FACTOR;

AGING; ARTICLE; BLOOD LEVEL; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC WOUND; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETIC FOOT; DRUG USE; ENVIRONMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; LEG ULCER; MODEL; PHYSIOLOGY; POPULATION; PRIORITY JOURNAL; SKIN; SKIN INJURY; WOUND FLUID;

ALPHA-AMYLASES; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DEXTRINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMAL GROWTH FACTOR; FIBROBLASTS; HUMANS; KERATINOCYTES; RECOMBINANT PROTEINS; WOUND HEALING;

EID: 77953248216     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp9002656     Document Type: Article

References (42)

1. Mekkes, J. R.; Loots, M. A. M.; Van der Wal, A. C.; Bos, J. D. Causes, Investigation and Treatment of Leg Ulceration Br. J. Dermatol. 2003, 148, 388-401
2. Davies, C. E.; Hill, K. E.; Newcombe, R. G.; Stephens, P.; Wilson, M. J.; Harding, K. G.; Thomas, D. W. A Prospective Study of the Microbiology of Chronic Venous Leg Ulcers to Reevaluate the Clinical Predictive Value of Tissue Biopsies and Swabs Wound Repair Regen. 2007, 15, 17-22
3. Harlin, S. L.; Willard, L. A.; Rush, K. J.; Ghisletta, L. C.; Meyers, W. C. Chronic Wounds of the Lower Extremity: A Preliminary Performance Measurement Set Plast. Reconstr. Surg. 2008, 121, 142-174
4. Price, P.; Harding, K. G. Cardiff Wound Impact Schedule: The Development of a Condition-Specific Questionnaire to Assess Health-Related Quality of Life in Patients with Chronic Wounds of the Lower Limb Int. Wound J. 2004, 1, 10-17
5. Herrick, S. E.; Sloan, P.; McGurk, M.; Freak, L.; McCollum, C. N.; Ferguson, M. W. J. Sequential Changes in the Histologic Pattern and Extra-Cellular Matrix Deposition During the Healing of Chronic Venous Leg Ulcers Am. J. Pathol. 1992, 1, 1085-1095
6. Goldman, R. Growth Factors and Chronic Wound Healing: Past, Present and Future Adv. Skin Wound Care 2004, 17, 24-35
7. Blakytney, R.; Jude, E. The Molecular Biology of Chronic Wounds and Delayed Healing in Diabetes Diabet. Med. 2006, 23, 594-608
8. Li, J.; Chen, J.; Kirsner, R. Pathophysiology of Acute Wound Healing Clin. Dermatol. 2007, 25, 9-18
9. Yager, D. R.; Chen, S. M.; Ward, S. I.; Olutoye, O. O.; Diegelmann, R. F.; Cohen, I. K. Ability of Chronic Wound Fluids to Degrade Peptide Growth Factors is Associated with Increased Levels of Elastase Activity and Dimished Levels of Proteinase Inhibitors Wound Repair Regen. 1997, 5, 23-32
10. Trengove, N. J.; Stacey, M. C.; MacAuley, S.; Bennett, N.; Gibson, J.; Burslem, F.; Murphy, G.; Schultz, G. Analysis of the Acute and Chronic Wound Environments: The Role of Proteases and Their Inhibitors Wound Repair Regen. 1999, 7, 442-452
11. Wlaschek, M.; Peus, D.; Achterberg, V.; Meyer-Ingold, W.; Scharfetter-Kochanek, K. Protease Inhibitors Protect Growth Factor Activity in Chronic Wounds Br. J. Dermatol. 1997, 137, 646-663
12. Wlaschek, M.; Scharffetter-Kochanek, K. Oxidative Stress in Chronic Venous Leg Ulcers Wound Repair Regen. 2005, 13, 452-461
13. Moseley, R.; Stewart, J. E.; Stephens, P.; Waddington, R. J.; Thomas., D. W. Extracellular Matrix Metabolites as Potential Biomarkers of Disease Activity in Wound Fluid: Lessons Learned from Other Inflammatory Diseases Br. J. Dermatol. 2004, 150, 401-413
14. Duncan, R. The Dawning Era of Polymer Therapeutics Nat. Rev. Drug Discovery 2003, 2, 347-360
15. Duncan, R. Polymer Conjugates as Anticancer Nanomedicines Nat. Rev. Cancer 2006, 6, 688-701
16. Vicent, M. J.; Duncan, R. (Eds) Polymer Therapeutics: Clinical Applications and Challenges for Development Adv. Drug Delivery Rev. 2009, 13) 61; whole issue
17. Shaunak, S.; Thomas, S.; Gianasi, E.; Godwin, A.; Jones, E.; Teo, I.; Mireskandari, K.; Luthert, P.; Duncan, R.; Patterson, S.; Khaw, P.; Brocchini, S. Polyvalent Dendrimer Glucosamine Conjugates Prevent Scar Tissue Formation Nat. Biotechnol. 2004, 22, 977-984
18. Vicent, M. J.; Perez-Paya, E. Poly-L-Glutamic acid (PGA) Aided Inhibitors of Apoptotic Protease Activating Factor 1 (Apaf-1): An Antiapoptotic Polymeric Nanomedicine J. Med. Chem. 2006, 49, 3763-3765
19. Duncan, R.; Gilbert, H. R. P.; Carbajo, R. J.; Vicent, M. J. Polymer Masked-Unmasked Protein Therapy (PUMPT). 1. Bioresponsive Dextrin-Trypsin and -MSH Conjugates Designed for α-Amylase Activation Biomacromolecules 2008, 9, 1146-1154
20. 2: A Novel Bioresponsive Anticancer Conjugate Biomacromolecules 2009, 10, 1358-1364
21. Gilbert, H.; Duncan, R. Polymer-Protein Conjugates for Triggered Activation: Hyaluronic Acid-Trypsin as a Model Proc. Cont. Rel. Soc. 2006, 33, 661
22. Hardwicke, J.; Ferguson, E. L.; Moseley, R.; Stephens, P.; Thomas, D. W.; Duncan, R. Dextrin-rhEGF Conjugates as Bioresponsive Nanomedicines for Wound Repair J. Controlled Release 2008, 130, 275-283
23. Frampton, J. E.; Plosker, G. L. Icodextrin. A Review of its Use in Peritoneal Dialysis Drugs 2003, 63, 2079-2105
24. Boukamp, P.; Petrussevska, R. T.; Breitkreutz, D.; Hornung, J.; Markham, A. Normal Keratinization in a Spontaneously Immortalized Aneuploid Human Keratinocyte Cell Line J. Cell Biol. 1988, 106, 761-771
25. Hreczuk-Hirst, D.; German, L.; Duncan, R. Dextrins as Carriers for Drug Targeting: Reproducible Succinoylation as a Means to Introduce Pendant Groups J. Bioact. Compat. Polym. 2001, 16, 353-365
26. Hreczuk-Hirst, D.; Chicco, D.; German, L.; Duncan, R. Dextrins as Potential Carriers for Drug Targeting: Tailored Rates of Dextrin Degradation by Introduction of Pendant Groups Int. J. Pharm. 2001, 230, 57-66
27. Cullen, B.; Smith, R.; McCulloch, E.; Silcock, D.; Morrison, L. Mechanism of Action of Promogran, a Protease Modulating Matrix, for the Treatment of Diabetic Foot Ulcers Wound Repair Regen. 2002, 10, 16-25
28. Irie, A.; Hunaki, M.; Bando, K.; Kawai, K. Determination of Amylase Activity in Serum and Urine using Blue Starch Substrate Clin. Chim. Acta 1972, 42, 63-66
29. Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxocity Assays J. Immunol. Methods 1983, 65, 55-63
30. Stephens, P.; Grenard, P.; Aeschlimann, P.; Langley, M.; Blain, E.; Errington, R.; Kipling, D.; Thomas, D.; Aeschlimann, D. Crosslinking and G-protein Functions of Transglutaminase 2 Contribute Differentially to Fibroblast Wound Healing Responses J. Cell Sci. 2004, 117, 3389-3403
31. Branca, P.; Rodriguez, M.; Rogers, J. T.; Ayo, D. J.; Moyers, J. P.; Light, R. W. Routine Measurement of Pleural Fluid Amylase in not Indicated Arch. Int. Med. 2001, 161, 228-232
32. Martin, P. Wound Healing-Aiming for Perfect Skin Regeneration Science 1997, 276, 75-81
33. Wall, I. B.; Moseley, R.; Baird, D. M.; Kipling, D.; Giles, P.; Laffafian, I.; Price, P. E.; Thomas, D. W.; Stephens, P. Fibroblast Dysfuction is a Key Factor in the Non-Healing of Chronic Venous Leg Ulcers J. Invest. Dermatol. 2008, 128, 2526-2540
34. Moseley, R.; Hilton, J. R.; Waddington, R. J.; Harding, K. G.; Stephens, P.; Thomas, D. W. Comparison of Oxidative Stress Biomarker Profiles between Acute and Chronic Wound Environments Wound Repair Regen. 2004, 12, 419-429
35. Lai, W. H.; Cameron, P. H.; Wada, I.; Doherty, J.; Kay, D. G.; Posner, B. I.; Bergeron, J. J. M. Ligand-Mediated Internalization, Recycling and Down-regulation of the Epidermal Growth Factor Receptor In Vivo J. Cell Biol. 1989, 109, 2741-2749
36. Breuing, K.; Andree, C.; Helo, G.; Slama, J.; Liu, P. Y.; Ericksson, E. Growth Factors in the Repair of Partial Thickness Porcine Skin Wounds Plast. Reconstr. Surg. 1997, 100, 657-664
37. Legrand, E. K. Preclinical Promise of Becaplermin (rhPDGF-BB) in Wound Healing Am. J. Surg. 1998, 176, 48S-54S
38. Smiell, J. M.; Wieman, T. J.; Steed, D. L.; Perry, B. H.; Sampson, A. R.; Schwab, B. H. Efficacy and Safety of Becaplermin (Recombinant Human Platelet-Derived Growth Factor-BB) in Patients with Nonhealing, Lower Extremity Diabetic Ulcers: A Combined Analysis of Four Randomized Studies Wound Repair Regen. 1999, 7, 335-346
39. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm048471.htm.
40. Veronese, F. M.; Harris, J. M., Eds. Peptide and protein PEGylation III: advances in chemistry and clinical applications. In Adv. Drug Delivery Rev. 2008, 60 (1), 1 ' 88.
41. Vicent, M. J.; Duncan, R., Eds. Polymer Therapeutics: Clinical Applications and Challenges for Development. In Adv. Drug Delivery Rev. 2009, 61 (13), 1117 - 1232.
42. Saltzman, W. M.; Olbricht, W. L. Building Drug Delivery into Tissue Engineering Nat. Rev. Drug Discovery 2002, 1, 177-186